Brief: Botanix Pharmaceuticals Planning For Approval From FDA For Sofdra In Mid-2024
08/11/2023 01:09
Nov 8 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX :
* IN MID-2024 WE ARE PLANNING FOR APPROVAL FROM FDA FOR
SOFDRA
Source text for Eikon: ID:nASX9771Qy
Further company coverage: BOT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million